What’s New for 2015 - C-Level Panel: Cutting Edge Insights on China’s Growing Biotech Market - China FDA Special Address - 80+ Key Expert Speakers from Asia’s leading Pharma & Biotech - 1 Joint Exhibition & Networking Area - 4 Days of Expert Knowledge Sharing - Revamped Program with New Special Focused Tracks & Sessions

1. 19 — 22 May 2015
Grand Hyatt Shanghai, China
IBC
LIFE SCIENCES
4th ANNUAL 5th ANNUAL 6th ANNUAL
Produced by:
www.biopharmaproduction.com
STILL the Leading Series in China with
Quality Content & a Strong Following of Top
Pharma & Biotech Stakeholders!
Yariv Hefez
Vice President Business
Development, Portfolio
Management, Strategy and
Partnering, Biosimilars Unit,
Merck, Switzerland
Richard O’Keeffe
Executive Director,
InternationalQuality–Japan-
Asia-Pacific (JAPAC) Regional
Quality Head,
Amgen, Singapore
Shou-Bai Chao
Senior Vice President, Bio
Ventures, Global Operations,
AstraZeneca, China
Lin Hong
Associate Director,
RegulatoryAffairs,AsiaPacific
Russia CIS (APAC),
Abbott, USA
Dr Ira Allen Jacobs
Oncology Portfolio Global
Medical Lead-Biosimilars,
Pfizer, USA
Dr. Martina A. Sersch
Global Clinical Lead, Oncology
Global Development, APAC
Biotherapeutics Lead,
Genentech, Inc. /
F. Hoffmann-La Roche Ltd.
Abdullah Baaj
CEO,
Boston Oncology, USA
Lars Dreesmann
Executive Director Upstream
Manufacturing & Tech
Transfer H84 & PT&PE H84,
Boehringer Ingelheim
Pharma, Germany
David Shen
Vice President,
NGMBiopharmaceuticals,
USA
Raj Mehta
President – Biotech,
Cadila Pharaceuticals Ltd,
India
Scott Liu
President & CEO,
Henlius Biopharmaceuticals,
USA
Li Shi
CEO,
Shanghai Zerun
Biotechnology, China
Pengfei Zhou
CEO,
Wuhan YZY Biopharma
Co Ltd, China
Our Distinguished Speaker Line Up
What’s New
for 2015
C-Level Panel: Cutting Edge
Insights on China’s Growing
Biotech Market
China FDA Special Address
80+ Key Expert Speakers from
Asia’s leading Pharma & Biotech
1 Joint Exhibition & Networking
Area
4 Days of Expert Knowledge
Sharing
Revamped Program with New
Special Focused Tracks &
Sessions
EXCLUSIVE
SITE TOUR!
Boehringer Ingelheim’s
New Biopharmaceuticals
Facility-Shanghai China
Peng Wang
President of R&D,
Yabao Pharmaceutical
Group, China
Life
Sciences

2. 08:00 Registration Opens & Morning Coffee
08:50 Welcome Address from IBC Asia
Ice Breaker: Exchange Business Cards & Get to Know Industry
Peers
09:00 Chairperson’s Opening Remarks
Abdullah Baaj, CEO, Boston Oncology, USA
09:10 Keynote Panel: Global Biopharma Outlook: Opportunities &
Challenges 2015 & Beyond
Moderator:
Yariv Hefez, Vice President Business Development, Portfolio
Management, Strategy and Partnering, Biosimilars Unit, Merck,
Switzerland
Panelists:
Abdullah Baaj, CEO, Boston Oncology, USA
Racho Jordanov, President & CEO, JHL Biotech, Taiwan
Richard O’Keeffe, Executive Director, International Quality – Japan-
Asia-Pacific (JAPAC) Regional Quality Head, Amgen, Singapore
Choose Your Own Sessions from 3 Different Tracks
4th ANNUAL
5th ANNUAL
6th ANNUAL
11:30 Chairperson’s Opening Remarks
Pengfei Zhou, CEO, Wuhan YZY Biopharma
Co Ltd, China
Chairperson’s Opening Remarks
Lin Hong, Associate Director, Regulatory Affairs,
Asia Pacific Russia CIS (APAC), Abbott, USA
Chairperson’s Opening Remarks
Dr Ira Allen Jacobs, Oncology Portfolio Global
Medical Lead-Biosimilars, Pfizer, USA
11:40
Efficient Screening Strategies to Select
Clones & Reduce Timelines
Chaomei He, Principal Scientist, Momenta
Pharmaceuticals, USA
Advances in Clone Screening &
Selection
Flexible Facilities & New
Biomanufacturing Technologies
Biosimilars Market Landscape
Fast-Tracking an Efficient Upstream Process
Transfer & Scale up of Biopharmaceutical
Processes
Lars Dreesmann, Executive Director Upstream
Manufacturing & Tech Transfer H84 & PT&PE H84,
Boehringer Ingelheim Pharma, Germany
Biosimilars on the Horizon: Opportunities
and Challenges
Dr Ira Allen Jacobs, Oncology Portfolio Global
Medical Lead-Biosimilars, Pfizer, USA
Analytical Strategies for Increased
Quality in Bioproduction
12:10
High-Throughput (HTP) Analytical Platforms
to Assess Product Quality Attributes in
Cell Lines
Senior Representative, Lonza
Hybrid MAb Facilities: Combining Single Use
Technology & Stainless Steel for China MAb
Facilities
Niels Guldager, Senior Technology Partner, NNE
Pharmaplan, Denmark
FindingSymbioticPartnershipstoAccelerate
Biosimilars Market Launches
Huiguo (Forrest) Hu, General Manager of
International Business, Shanghai CP Guojian
Pharmaceutical Co., Ltd, China
12:50
Networking Lunch & VIP Tables
VIP Table 1: Robin Tan, Head of Analytical Technologies, Shanghai CP Guojian Pharmaceutical, China
VIP Table 2: Shou-Bai Chao, Senior Vice President, Bio Ventures, Global Operations, AstraZeneca, China
VIP Table 3: Michelle Yu Xia, Chairman, President & CEO, Akeso Biopharma, China
VIP Table 4: Paul Thomas, Business Unit Head – Biosimilars, Biocon, India
VIP Table 5: Dr Jiang WeiDong, Chief Science Officer and Vice President, Henlius Biopharmaceuticals, USA
VIP Table 6: Huiguo (Forrest) Hu, General Manager of International Business, Shanghai CP Guojian Pharmaceutical Co., Ltd, China
VIP Table 7: Peng Wang, President of R&D, Yabao Pharmaceutical Group, China
VIP Table 8: Zou Ping, Vice Director, Shanghai CPGJ Pharma, China
VIP Table 9: John Xu, CSO, Shanghai Benemae Pharma & VP, Shanghai Mabicine, China
Exchange business cards and have
an informal chat with key experts
during the networking lunch!
Roundtable Discussions
Each leader will facilitate the discussion for 45 minutes. Leaders will then share key takeaways on the stage for 5 minutes each.
Choose your table now! Email Gladys.Landicho@ibcasia.com.sg
2:30
Roundtable 4: GMP Regulation
Lin Hong, Associate Director, Regulatory Affairs,
Asia Pacific Russia CIS (APAC), Abbott, USA
Roundtable 5: Quality by Design
Kevin Zen, Senior Manager, Biologics
Development, Allergan, USA
Roundtable 6: R&D Investment &
Development
Fei Jiang, Director, Business Development,
3SBio, China
09:45 CEO Panel: Cutting Edge Insights into China’s Growing Biotech
Market
Moderator:
Shou-Bai Chao, Senior Vice President, Bio Ventures, Global Operations,
AstraZeneca, China
Panelists:
Joe Zhou, CEO, Walvax Group, China
Li Shi, CEO, Shanghai Zerun Biotechnology, China
Michelle Yu Xia, Chairman, President & CEO, Akeso Biopharma, China
Scott Liu, President & CEO, Henlius Biopharmaceuticals, USA
10:20 Government Address: China’s Evolving Biopharma Policies &
Regulations
Senior Representative, China Food and Drug Administration (CFDA),
China
10.45 Morning Networking & Refreshment Break
Roundtable 7: Emerging InvestmentTrends
in Biosimilars and Portfolio Management
James Huang, Managing Partner, KPCB, China
Roundtable 8: Bringing Biosimilars to the
Market
DrVilloo Patell, Founder, Chairperson and CEO,
Avesthagen, India
Roundtable 9: Regulatory Pathway in China
ShaoyuChen, Partner;ManagingDirector,China
Food and Drug Practice, Covington & Burling
LLP, China
Roundtable 1: Novel Cell Line Development
and Bioprocess Approaches for Increased
Speed, Titer and Product Quality
Cheng Zhang, CSO, Gmax Biopharm, China
Roundtable 2: Strategies on Raw Material
and Supplier Management for Efficient, Cost-
effective Biopharmaceutical Production
Chiali Liu, Manager, Microbial and Cell Culture
Development, GSK, USA
Roundtable 3: Applying Essential QbD
concepts in Cell Culture and Bioprocess
Deveopment for Biopharmaceuticals
Hung Fai Poon, Director, Cell Culture, Hisun
3:30
CONFERENCE DAY ONE 20 MAY 2015 WEDNESDAY
4:00 Integrating Multi-Omics Analysis & in silico
Modelling of CHO cells for Enhancing Cell
Culture Performance and Product Quality
Dong-Yup Lee, Assistant Professor, Department
of Chemical and Biomolecular Engineering, NUS
Commercialization & Scale - Up
Strategies
Case Study: Manufacturing Complex
Biosimilars
Hui Hu, Vice Director, CPGJ Research Institute,
Shanghai CP Guojian Pharmaceutical, China
Update on Biosimilars Regulations &
Guidelines
Case Study: Developing Biosimilars under
CFDA Guideline
WenYong, ViceDirector,DrugResearchInstitutes,
Biopharmaceutical Institute, Jiangsu
AoSaiKang Pharmaceutical Co Ltd, China
Customer Service Hotline +65 6508 2401 register@ibcasia.com.sg www.biopharmaproduction.com
Afternoon Networking & Refreshment Break
Biopharma Visionary Keynote Sessions
Novel ‘Omics Approaches for
Enhanced Quality’

3. 4:40
Cell Culture Media for
Optimized Growth
Individual Optimization of Chemically
Defined Media
ChuanHe, ProcessDevelopment,SeniorScientist,
Beijing Mabworks Biotech, China
Panel Discussion: Overcoming Challenges of
Scale-Up: Moving Strains from Bench to
Large-Scale Fermentation & Product Recovery
Panelists:
Lei Sun, Vice President, Technology and
Manufacture, AutekBio, China
Weidong Jiang, Chief Scientific Officer and Senior
Vice President, Shanghai Henlius Biotech, China
Hung Fai Poon, R&D Director, Cell Culture, Hisun
Pharmaceutical, China
Regulatory Challenges and Development in
the US and Europe
AndreaLaslop, HeadofScientificOffice,Austrian
Agency for Food and Health Safety, Austrian
Member, European Medicines Agency
5:15
Case Study: Key Criteria in Developing and
Gaining Approval in Biosimilars
Dr Shin Jae Chang, Vice President, Celltrion,
Korea
High Throughput & High Resolution
Glycosylation Analysis Throughout
Bioprocess Development for Improved
Quality
Dr Zhang Peiqing, Research Scientist,
Bioprocessing Technology Institute, A*Star
Singapore
5:50 Chairperson’s Summary
Networking Cocktail
VIP 1: Eric Morfin, Senior Director, Project Management and Operational Excellence, Allergan Biologics, USA
VIP 2: Lin Hong, Associate Director, Regulatory Affairs, Asia Pacific Russia CIS (APAC), Abbott, USA
VIP 3: Michael Grogan, Head of International Logistics & Distribution, Technical Operations, Shire Pharmaceuticals, Ireland
VIP 4: Dr Vivek Mittal, Head – Legal, Lupin, India
VIP 5: David Shen, Vice President, NGM Biopharmaceuticals, USA
VIP 6: Raj Mehta, President – Biotech, Cadila Pharaceuticals Ltd, India
VIP 7: Scott Liu, CEO, Henlius Pharmaceuticals, USA
VIP 8: Feng Tian, Head and Director, Ambrx China
VIP 9: Wen-Chen Suen, Chief Scientific Officer, Biologics Division, HEC Pharm, China
6:00
Exchange business cards and have
an informal chat with key experts
during the networking cocktail!
7:00 End of Conference Day One
4th ANNUAL
5th ANNUAL
6th ANNUAL
9:00
9:10
Novel Cell line Development Platforms
& Expression Systems
9:50
Chairperson’s Opening Remarks
Hung Fai Poon, Director, Cell Culture, Hisun
Pharmaceuticals, China
Chairperson’s Opening Remarks
Lin Hong, Associate Director, Regulatory Affairs,
Asia-Pacific, Russia CIS (APAC), Abbott, USA
Chairperson’s Opening Remarks
Raj Kannan, Vice President, Commercial Head,
Biosimilars, Merck, Switzerland
Analyzing Cell Line Development Platforms
& Amgen Case Study of Novel Expression
Systems
Dayou Liu, Senior Scientist, Amgen, USA
Global Biotech Advances
Case Study: Supply Security & Quality in 21st
Century Biotech
RichardO’Keeffe, ExecutiveDirector,International
Quality – Japan-Asia-Pacific (JAPAC) Regional
Quality Head, Amgen, Singapore
Latest Biosimilars Technology
& Best Practice Tech Transfer
Case Study:Tips for SuccessfulTechTransfers
Dr Joe Xin Hua, Zhou, Chief Executive Officer,
Walvax Group, China
Panel Discussion: Getting the most out of
Stable versusTransient Expression Systems
Panelists:
XiangYang Zhu, CEO, Huaota Biopharm, China
Dayou Liu, Senior Scientist, Amgen, USA
Cheng Zhang, CSO, Gmax Biopharm, China
Disposable & Stainless Steel HybridTechnique
Used for the Implementation of a New Process
Johannes Salzbrunn, Head of GMP Downstream
/ Fill & Finish, Boehringer Ingelheim Shanghai
Pharmaceuticals, China
SMARTTechnologies – More than Evolution
for Biosimilars
Dr Barbara Paldus, CEO, Finesse Solutions,
Inc., USA
Morning Networking & Refreshment Break10:30
CONFERENCE DAY ONE 20 MAY 2015 WEDNESDAY
CONFERENCE DAY TWO 21 MAY 2015 THURSDAY
TRACK A: FACILITIES TRACK B: PRODUCTION
New Projects Process & Quality
11:00
Using Targeted Genome
Engineering to Advance CHO Cell
Technology
Dr Jamie Freeman, Bioproduction
Product Manager, Horizon
Discovery, U.K
Case Study: Defining Specific
Critical Quality Attributes in
Different R&D Processes
Cuihua (Chloe) Liu, Executive Vice
President, Quality & Regulatory
Affair, Alphamab, China
Case Study: New Antibody
Facility in China
Jason Li, Senior Director,
Downstream Processing,
Genor Biopharma, China
Redefining Consistency and
Reducing Risk with Cell Culture
Media and Supplementation
Senior Executive, BD Advanced
Bioprocessing
Choose Your Own Sessions from 4 Different Tracks
4th ANNUAL 5th ANNUAL
6th ANNUAL
5th ANNUAL
Customer Service Hotline +65 6508 2401 register@ibcasia.com.sg www.biopharmaproduction.com
Examining Design Principles when
Transforming to Flexible Biomanfacturing
Facilities
Strategies for Optimising Glycoslation

4. 11:40
Overcoming the‘Position Effect’
– Targeting Integration into
Chromosomal Hotspots for
Rapid Cell Line Development
Yuan Sheng Yang, Senior Staff
Research Scientist, Bioprocessing
Technology Institute, Singapore
Case Study: Building an
AntibodyManufacturingFacility:
Path of a Start-Up Company
Cheng Zhang, Chief Scientific
Technology Officer, Gmax
BioPharm, China
Case Study: Insect Cell-
Baculovirus System for
Innovative Vaccine Production
John Zeng, Executive Vice
President, Product Development
and Clinical Manufacturing,
Shanghai Zerun Biotech,
China
Productive Development
Partnerships (PDP) &
Biosimilar Investments
PDP and the Biosimilar
Opportunity in LATAM
Yariv Hefez, Vice President Business
Development, Portfolio
Management, Strategy and
Partnering, Merck, Switzerland
12:20
Efficient Bioprocess Design
& Scaling Up Strategies
Bioprocess Design Strategies to
Increase Quality and Efficiency
Zhiwei Pan, Senior Director, Cell
Culture Process Development,
Livzon mAbpharm, China
Case Study: Manufacturing &
Applications of Oligonucleotides
for Research, Diagnostics &
Therapeutics in China
Dmitry Samarsky, Executive
Vice President, Technology &
Business Development, RiboBio,
China
Case Study: Production, Quality
Control & Clinical Approval
Process of TK006, A Denosumab
Biosimilar
Yan Shan Huang, Senior Vice
President, Antibody Pharmaceutics,
JiangsuT-mab Biopharma, China
Identifying the Best Investment
Model and Valuating Biosimilar
Opportunities
Dr Patrik Frei, CEO, Venture
Valuation VV Asia, Singapore
1:00
Networking Luncheon & VIP Tables
VIP Table 1: Masih Sabet, Associate Director Quality Assurance, APAC Technology Operation, UCB, China
VIP Table 2: Cuihua (Chloe) Liu, Executive Vice President, Quality & Regulatory Affairs, Alphamab, China
VIP Table 3: Zhonghui Lian, Deputy Chief Engineer, Technical Service Department, Beijing Yizhuang Biomedical Park, China
VIP Table 4: Ko Chung Lin, Chief Executive Officer, PharmaEssentia Corporation, Taiwan
VIP Table 5: Raj Kannan, Vice President, Commercial Head, Biosimilars, Merck, Switzerland
VIP Table 6: Dr. Martina A. Sersch, Global Clinical Lead, Oncology Global Development, APAC Biotherapeutics Lead,
Genentech, Inc. / F. Hoffmann-La Roche Ltd.
VIP Table 7: Pengfei Zhou, CEO, Wuhan YZY Biopharma Co Ltd, China
VIP Table 8: Andy Tsun, Senior Manager & Group Head, Novel Drug and Cell Line Development, Innovent Biologics, China
VIP Table 9: Xiang Yang Zhu, CEO, Huaota Biopharm, China
Bring your questions
and visit the
guests during the
networking lunch!
2:00
Biomanufacturing Project
Design & Planning
Efficient Cell Culture Process
Development & Case Study of
Single-use Bioreactors
Hao Chen, Principal Scientist,
Merck, USA
Best Practices for Executing
Seismically Safe Medical New
Facilities
Eric Morfin, Senior Director, Project
Management and Operational
Excellence, Allergan Biologics, USA
Successfully Applying Quality
by Design (QbD) Concepts to
Develop a Robust Protein
Therapeutic Formulation
Kevin Zen, Senior Manager,
Biologics Development,
Allergan, USA
Market Access and
Commercialization
Case Study: Developing
Biosimilars/Biobetters in
Emerging and Regulated
Markets
Ko Chung Lin, Chief Executive
Officer, PharmaEssentia
Corporation, Taiwan
2:40
Biomanufacturing
Finance & Investment
Technology Transfer &
cGMP
Developing a Strategy for
Successful Scale Up
Chiali Liu, Manager,
Microbial and Cell Culture
Development, GSK, USA
Case Study: Financing &
Investing in Biomanufacturing
Facilities in China
Peter Fuhrman, Chairman & CEO,
China First Capital, China
Case Study: EfficientTechnology
Transfer in Asia Whilst
Complying with cGMP
Xiaoyong(Sam)Wu, OSDTechnical
Lead, AstraZeneca, China
Developing Commercial
Strategies to Optimize Market
Uptake
Raj Kannan, Vice President,
Commercial Head, Biosimilars,
Merck, Switzerland
3:20 Afternoon Networking & Refreshment Break
3:50
Biomanufacturing Supply
Chain Efficiencies
Panel Discussion: Insights into
Next-Generation Bioprocessing
Moderator:
Prof Rolf G Werner, Industrial
Biotechnology Department,
University ofTubingen, Germany
Panelists:
Chiali Liu, Manager, Microbial and
CellCultureDevelopment, GSK, USA
Hao Chen, Principal Scientist,
Merck, USA
Zhiwei Pan, Senior Director, Cell
Culture Process Development,
Livzon mAbpharm, China
Commercial Viability of
Antibody Drug Investment
& Development
Case Study: Distributing
Biologics in Multiple Growing
Markets Efficiently
Michael Grogan, Head of
InternationalLogistics&Distribution,
Technical Operations, Shire
Pharmaceuticals, Ireland
Panel Discussion: Risks and
Opportunities in Biosimilars/
Biobetters and Key Enablers for
Advancement
Moderator:
Salman Bokhari, Managing
Director, Sidrapex, Singapore
Panelists:
Atul Deshpande, Associate
Director, Unit Strategy Office, Asia
Pacific Therapeutic Strategy Unit,
Sanofi, China
PaulThomas, Business Unit Head –
Biosimilars, Biocon, India
Ko Chung Lin, Chief Executive
Officer, PharmaEssentia
Corporation, Taiwan
Tadashi Matsumoto, President/
Chief Executive Officer, Reqmed Co
Ltd, Japan
Green & Energy Efficient
Biomanufacturing Facilities
4:30
Case Study: Going Green in
Biomanufacturing
Case Study: Cold Chain
Management from
Manufacturing to Distribution of
Biologics
Masih Sabet, Associate Director
QualityAssurance,APACTechnology
Operation, UCB, China
Biosimilars Clinical Trials
Development: Key
Considerations in Planning and
Execution
Dr Arun Maseeh, Vice President,
Medical Affairs, Cadila
Pharmaceuticals, India
Clinical
Development
5:10
5:15
Chairperson’s Summary & End of Conference
End of the BDP Week Conferences 2015
CONFERENCE DAY TWO 21 MAY 2015 THURSDAY
TRACK A: FACILITIES TRACK B: PRODUCTION
4th ANNUAL 5th ANNUAL
6th ANNUAL
5th ANNUAL
Customer Service Hotline +65 6508 2401 register@ibcasia.com.sg www.biopharmaproduction.com
Analytical Strategies for Defining
CQA in QbD Bioprocess
Development
Next Generation
Bioprocessing Trends

5. Session 3: Complexity of Monoclonal
Antibodies and Clinical Challenges for
Establishing Biosimilarity
Dr. Martina A. Sersch, Global Clinical Lead,
Oncology Global Development, APAC
Biotherapeutics Lead, Genentech, Inc. / F.
Hoffmann-La Roche Ltd.
Session 4: Proven Scalability of a Predefined
Process in Bringing Biosimilar mAbs to
Market
David Shen, Vice President, NGM
Biopharmaceuticals, USA
BestPracticesinProcessTechnologyTransfer
and cGMP Manufacturing
Hao Chen, Principal Scientist, Merck, USA
Exclusive SiteTour to Boehringer Ingelheim’s
New Biopharmaceuticals Facility in Shanghai,
China
PRE-CONFERENCE WORKSHOPS 19 MAY 2015 TUESDAY
POST-CONFERENCE WORKSHOPS 22 MAY 2015 FRIDAY
9.30am–12.30pm
4th ANNUAL
5th ANNUAL
6th ANNUAL
Customer Service Hotline +65 6508 2401 register@ibcasia.com.sg www.biopharmaproduction.com
Workshop A Workshop A Special Focus Day A
Monoclonal Antibodies (Mabs)
Session 1:Trends, Challenges and Strategies
for Biosimilar Therapeutic Antibody
Development
Dr Sunit Maity, AVP – Product Development,
Theramyt Novobiologics Private Limited,
India
Session 2: Next Generation of Mabs
Jinming Gu, Senior Scientist, AbbVie
Bioresearch Center, USA
Achieving Operational Excellence in
Bioprocessing: Design of Experiments (DoE)
applications for Cell Culture
Hung Fai Poon, R&D Director, Cell Culture
Hisun Pharma (Hangzhou), China
Boehringer Ingelheim Biopharmaceuticals
Move to China - Operational Excellence and
Experience in 30 years Commercial
Manufacturing
Dr. Jian Huang, Director, Business Development
& Key Account Management, Boehringer
Ingelheim Biopharmaceuticals, China
12.30pm – 1.30pm Networking Lunch
1.30pm–5.00pm
4th ANNUAL
5th ANNUAL
6th ANNUAL
Special Focus Day C Workshop B Workshop B
Special Focus Day (Continued)
9.30am–12.30pm
Chairperson’s Opening Remarks
Weidong Jian, CSO & VP, Henlius
Biopharmaceuticals, USA
Strategies for Novel Antibodies and
Biosimilars Development
Pei Ye, Vice President, Beijing Mabworks
Biotech, China
Novel Methods in Antibody Discovery and
Characterization
Weidong Jian, CSO & VP, Henlius
Biopharmaceuticals, USA
Strategies in Cell line engineering of
Bi Specific Antibodies
Pengfei Zhou, CEO, Wuhan YZY Biopharma
Co Ltd, China
Boosting Productivity and Efficiency of
Biotherapeutics
Prof Rolf G Werner, Industrial Biotechnology
Department, University ofTubingen, Germany
Crafting Successful Market Access
Strategies for Biosimilars in Emerging
Markets
Salman Bokhari, Managing Director,
Sidrapex, Singapore
Best Corrective & Preventive Action (CAPA) &
Root Cause Analysis Practices for
Biomanufacturing Excellence
Eric Morfin, Senior Director, Project Management
and Operational Excellence, Allergan Biologics,
USA
12.30pm – 1.30pm Networking Lunch
Gaining Approval for Biosimilars in the US
and Europe
Dr. Onesmo Mpanju, Principal Consultant,
Independent Biopharmacuetical Product
Development Consultant, Former Review
Scientist of FDA
Alan Liss, ConsultanttoPharmaceuticalIndustry,
Former Review Scientist of FDA, USA
Novel Strategies in Monoclonal Antibodies
Targeting GPCRs
Cheng Zhang CSO, Gmax Biopharm, China
Strategies in Fc Effector Function Analysis
in Antibodies
Jingyi Xiang,Head of Bioanalytics, Eureka
Pharma, USA
Engineering of Antibody Drug Conjugates
(ADCs) technologies
Chairman Closing Remarks and End of
Post-Conference Special Focus Day
Best Corrective & Preventive Action (CAPA) &
Root Cause Analysis Practices for
Biomanufacturing Excellence (Continued)
Eric Morfin, Senior Director, Project Management
and Operational Excellence, Allergan Biologics,
USA
1.30pm–5.00pm
Add Value to Your Learning with
Interactive Workshops, Focus Days &
a Site Tour to Choose From!
Site TourWorkshop B
Special Focus Day C (Continued) Workshop B (Continued) Workshop C

6. 19 — 22 May 2015
Grand Hyatt Shanghai, China
IBC
LIFE SCIENCES
4th ANNUAL 5th ANNUAL 6th ANNUAL
IBC’s Biopharma Development & Production
Week is the leading industry platform for
pharma, biotech, CMOs, CROs, research
institutes, investors and industry stakeholders
to meet, network and discuss current industry
trends, establish business partnerships and be
updated on investment opportunities in China
and surrounding Asia.
GEOGRAPHY
■ China 50%
■ Rest of North Asia 15%
■ Southeast Asia & India 10%
■ Europe 10%
■ US 10%
■ Rest of the World 5%
Who Shoud Attend
Chairman/Chief
Executive Officer
Chief Operations
Officer
Chief Scientific Officer
Chief Technology
Officer
Chief Marketing Officer
Senior Vice President
Vice President
Biologics
Vice President
Biosimilars
Vice President of R&D
Vice President of
Manufacturing
Vice President of
Facilities
Head of Cell Line
Development
Principal Scientist
Head Process
Development
General Manager
Director
Business Development
Sales & Marketing
Manager
INDUSTRY
■ Pharmaceuticals/Biotech
50%
■ CMOs 15%
■ CROs 15%
■ Technology & Solution
Providers 10%
■ Finance/Law 10%
Abundant
Networking Opportunities
& Interactive Formats
80+ Top Level Speakers
New Pre & Post Workshops
5+ Interactive Panel Discussions
Hot Topic Round Table Discussions
Meet the Experts Via Specially Hosted VIP Lunch Tables
Speed Networking Sessions to Get to Know Your Peers
Conference Networking Cocktail
3 Co-located events under one roof
• 4th Annual Cell Line Development &
Engineering
• 5th Annual Biomanufacturing
• 6th Annual Biosimilars Asia
Revamped program including special focused
tracks on:
• Biomanufacturing Facilities
• Biomanufacturing Production
• Monoclonal Antibodies
• Cutting Edge Trends in Antibody Development
Special Site Tour & Workshop to Boehringer Ingelheim’s new biopharma
facility
Establish Business Partnerships with local Chinese drug developers and
contract manufacturers
Learn technical & practical know how from experiences on the ground in Asia-
Pacific
Showcase your cutting edge solutions in front of key China/Asian Biopharma
decision makers
Speed Networking to get to know your industry peers
Top Reasons Why You
Should Participate:
3SBio • Abbott • AbbVie Bioresearch Center • Agilent Technologies • Akeso Biopharma • Allergan • Allergan Biologics • Alphamab • Ambrx China • Amgen • Anitia OíConnor Consulting
• Astrazeneca • Autekbio • Avesthagen • BD Advance Bioprocessing • Beijing Mabworks Biotech Co Ltd • Beijing Yizhuang Biomedical Park • Biocon • Bioprocessing Technology Institute
• Boehringer Ingelheim Biopharmaceuticals • Boehringer Ingelheim Pharma • Boehringer Ingelheim Shanghai Pharmaceuticals • Boston Oncology • Cadila Pharmaceuticals • Celltrion
• China First Capital • Covington & Burling LLP • CPC • CPGJ Pharma • Eureka Therapeutics, Inc. • European Medicines Agency • FDA • FEF • Finesse Solutions, Inc • Genentech, Inc. / F.
Hoffmann-La Roche Ltd. • Genscript • Genor Biopharma • Gmax Biopharm • GSK • Hanwha Chemical • Henlius Biopharmaceuticals • Hisun Pharma (Hangzhou) Co Ltd • Hisun Pharmaceutical
• Horizon Discovery • Huaota Biopharm • Innovent Biologics, Inc. • JHL Biotech • Jiangsu AoSaiKang Pharmaceutical Co Ltd • Jiangsu T-mab Biopharma • JS Biosciences • JX Nippon Oil
& Energy • KPCB • Livzon mAbpharm • Lonza • Lupin Limited • MedImmune • Merck • Momenta Pharmaceuticals • NGM Biopharmaceuticals • NNE Pharmaplan • NUS • Pfizer • PharmaEssentia
Corporation • Reqmed Co Ltd • RiboBio • Shanghai Benemae pharma • Shanghai CP Guojian Pharmaceutical • Shanghai Henlius Biotech • Shanghai Zerun Biotechnology • Shen Zhen
DongYangGuang Industry Co, HEC R&D Centre • Shire Pharmaceuticals • Sidrapex • Solentim • Theramyt Novobiologics Private Limited • UCB • University of Tubingen, Germany • Venture
Valuation VV Asia • Walvax Group • Wuhan YZY Biopharma Co Ltd • Yabao Pharmaceutical Group • Yong Loo Lin School of Medicine, NUS
The Following Companies Have Already Confirmed their Attendance!
Here’s What Past Attendees Have to Say!
“Valuable, world-class and professionally-organized, this conference was
among the very best I’ve ever attended.”
Peter Fuhrman, Chairman & Chief Executive Officer, China First Capital
“It is a great opportunity to learn biomanufacturing in China.”
Kang Li, Head of Biologics, Beigene
“Very insightful conference with a broad range of issues discussed and
excellent speakers.”
Ramesh Rajentheran, Managing Director, Head – Asian
Healthcare, Investment Banking, Barclays
Customer Service Hotline +65 6508 2401 register@ibcasia.com.sg www.biopharmaproduction.com

7. Exhibitor
Floor Plan 2015
Grand Hyatt Shanghai
1.5m
1.5m
1.5m
1.5m
1.5m
19 18
17 16 15 14 13 12
23 24 25
27 28 2926
20
21
1 2
3 4 5 6
11
10
9
8
7
6.30m6.57m
Booked
Booked
Booked Booked
Reserved Reserved
Entrance
Entrance
22
Booked Booked Booked
Booked Booked
Booked Reserved Booked
Booked Booked
Booked Booked
Booked
Booked
4th ANNUAL 5th ANNUAL 6th ANNUAL
19-22 May 2015
GRAND HYATT SHANGHAI
CHINA
International Marketing Partner:
Media Partners:
Customer Service Hotline +65 6508 2401 register@ibcasia.com.sg www.biopharmaproduction.com
SPONSORSHIP & EXHIBITION
GOLD SPONSOR BRONZE SPONSORS
ASSOCIATE SPONSORS SESSION SPOTLIGHT SPONSORS
EXHIBITORS
Associations:
Why You Should Sponsor
Position your brand as the market leader in the biopharma industry
Stand out amidst competition
Showcase your latest technologies and solutions
Generate new business contacts
Strengthen existing relationships and partnerships in the industry
For more information about how you can leverage on our
events to optimize your marketing budget and reach your
target audience, please contact: Ms. Yvonne Leong at
Tel: +65 6508 2489 Email: Yvonne.leong@ibcasia.com.sg

8. 20 - 21 May 2015 • Tick the Main Conference of Interest
❑ 4th Cell Line Development & Engineering
❑ 6th Biosimilars Asia
❑ 5th Annual Biomanufacturing
19 & 22 May • Tick the Workshop(s) You Would Like to Attend
19 May • Pre-Conference 0.5 Day Workshops
❑ 9.00am - 12.30pm • Best Practices in Process Technology Transfer & cGMP
❑ 1.30pm - 5.00pm • Achieving Operational Excellence in Bioprocessing
19-May • Pre-Conference 1 Day Workshop
❑ 9.00am - 4.00pm • Monoclonal Antibodies
❑ 9.00am - 4.00pm • Boehringer Ingelheim Move to China (Incl. Site Tour)
22 May • Post-Conference 0.5 Day Workshops
❑ 9.00am - 12.30pm • Market Access Strategies for Biosimilars in Emerging Markets
❑ 1.30pm - 5.00pm • Gaining Approvals for Biosimilars in the US & Europe
22-May • Post-Conference 1 Day Workshops
❑ 9.00am - 4.00pm • Cutting Edge Trends in Antibody Development
❑ 9.00am - 4.00pm • Best CAPA & Root Cause Analysis Practices for Biomanufacturing
If undelivered, please return to:
111 Somerset Road,
TripleOne Somerset #10-06, Singapore 238164
Tel: +65 6508 2400 Fax: +65 6508 2408
BIOPHARMA DEVELOPMENT & PRODUCTION
Email
register@ibcasia.com.sg
Fax
+65 6508 2407
Scan the QR Code with your
smartphone and register today
Customer Service Hotline
+65 6508 2401
MAIL the attached registration
form with your cheque to
IBC Asia (S) Pte Ltd
c/o Informa Regional Business
Services
111 Somerset Road,
TripleOne Somerset #10-06,
Singapore 238164
Web
www.biopharmaproduction.com
HOTEL INFORMATION
DATA PROTECTION
PAYMENT TERMS
CANCELLATIONS / SUBSTITUTION
IMPORTANT NOTE
REGNO.200108203N
Payment must be received 10 business days prior to the event.
To take advantage of discounts with an expiry date, registration
and payment must be received by the cut-off date.
• Payment by bankers draft or cheque in S$ or US$ should be
made in favour of “IBC Asia (S) Pte Ltd” and mailed to:
IBC Asia (S) Pte Ltd
c/o Informa Regional Business Services
111 Somerset Road, TripleOne Somerset #10-06
Singapore 238164
Attn: The Accounts Receivable Team
• Payment by bank transfer in S$ or US$ made payable to:
IBC Asia (S) Pte Ltd
A/C No.:147-059513-001 (S$)
A/C No.:260-457866-178 (US$)
The Hongkong and Shanghai Banking Corporation Limited
21 Collyer Quay, HSBC Building
Singapore 049320
Bank Swift Code: HSBCSGSG
Bank Code: 7232
• Payment by Credit Card (AMEX, VISA or MasterCard).
The best way to pay by credit card is through our secure
portal built into the website. To pay by phone please indicate
the contact name and details below and our Customer
Services Team will call within 24 hours to take payment.
Please do not send credit card information by email.
The personal information entered during your registration/order,
or provided by you, will be held on a database and may be
shared with companies in the Informa Group in the UK and
internationally. Occasionally, your details may be obtained from
or shared with external companies who wish to communicate
with you offers related to your business activities. If you do not
wish your details to be used for this purpose, please contact
our Database Department at Email: database@ibcasia.com.sg,
Tel: +65 6508 2400 or Fax: +65 6508 2408.
Should you be unable to attend, a substitute delegate is
welcome at no extra charge. Cancellations must be received in
writing at least 10 business days before the start of the event,
to receive a refund less 10% processing fee per registration.
The company regrets that no refund will be made available for
cancellation notifications received less than 10 business days
before the event.
Please quote the name of the delegate, event title and invoice
number on the advice when remitting payment. Bank charges
are to be deducted from participating organisations own accounts.
Please fax your payment details (copy of remittance advice,
cheque or draft to +65 6508 2407).
Attendance will only be permitted upon receipt of full payment.
Participants wishing to register at the door are responsible to
ensure all details are as published. IBC assumes no further
liability or obligation, beyond the refund of the paid registration
fee, in the event of postponement or cancellation by IBC.
6 EASY WAYS TO REGISTER
RESERVE YOUR PLACE TODAY!
■ Yes! I/We will attend the Biopharma Development & Production
19 – 22 May 2015, Grand Hyatt Shanghai, China
■ I would like to purchase the conference presentations at SGD1000 + GST (SGD1070) per log in.
CREDIT CARD PAYMENTS
The best way to pay by credit card is through our secure on-line registration process, simply log on to the website at
www.biopharmaproduction.com and click “Register On-line”. If you would prefer to pay over the phone please complete the contact
name and details and our Customer Services Team will call within 24 hours to take payment. As we treat your credit card information
in the strictest confidence, please do not send payment details by email.
Credit card contact: Department:
Direct phone number: Email:
P46271
■ I enclose my bankers draft / cheque payable to IBC Asia (S) Pte Ltd
■ I am paying by bank transfer (copy attached)
■ Payment by Credit Card. (AMEX, VISA or MasterCard accepted)
PAYMENT METHOD
(Please tick)
• Multiple Bookings Discount pricing is applicable to groups of 3 or more delegates from the same organisation registering for the same event, at the same time.
Fee stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR special rate OR group rate.
• All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.
• Registration fees are subject to the prevailing government tax.
Early Bird Rate
Register & pay on or
before 13 Mar 2014
Special Rate
Register & pay on or
before 10 Apr 2015
Group Rate
(3 or more delegates)
Normal Rate
Register & pay after
10 Apr 2015
❑ 2 Day Conference only
FEE PER DELEGATE
❑ 4 Day Package USD 2,795 USD 2,995 USD 3,195 USD 2,595
❑ 3.5 Day Package
❑ 3 Day Package
❑ 2.5 Day Package
USD 2,595 USD 2,795 USD 2,995 USD 2,395
USD 2,395 USD 2,595 USD 2,795 USD 2,195
USD 2,095 USD 2,295 USD 2,495 USD 1,895
USD 1,795 USD 1,995 USD 2,195 USD 1,595
CNY 7,500 CNY 8,500 CNY 9,000 CNY 7,000
CNY 7,000 CNY 8,000 CNY 8,500 CNY 6,500
CNY 6,500 CNY 7,500 CNY 8,000 CNY 6,000
CNY 6,000 CNY 7,000 CNY 7,500 CNY 5,500
CNY 5,500 CNY 6,500 CNY 7,000 CNY 5,000
Grand Hyatt Shanghai, China
Jin Mao Tower, 88 Century Boulevard
Pudong, Shanghai 200121
Tel: +86 21 5049 1234 | Fax: +86 21 5049 8381
Contact Person: Judy Xu
Email: judy.xu@hyatt.com
Domestic China Companies (Global Headquaters Located within Mainland China)
International Companies (Global Headquaters Located Outside of Mainland China)
Register 3 Delegates and
The 4th Attends For Free!
Customer Service Hotline +65 6508 2401 register@ibcasia.com.sg www.biopharmaproduction.com
❑ 2 Day Conference only
❑ 4 Day Package
❑ 3.5 Day Package
❑ 3 Day Package
❑ 2.5 Day Package
4th ANNUAL 5th ANNUAL 6th ANNUAL